Sign in
Taking peopleNo phase

UCAN CAN-DU: Canada-Netherlands Personalized Medicine Network in Childhood Arthritis and Rheumatic Disease

Key facts

Who runs it
The Hospital for Sick Children
Where
Canada and Netherlands19 sites in 2 countriesChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
4,100 people, planned
Started
24 Aug 2018
Expected to end
30 Mar 2027
Type of study
Observational, 4 groups
Record updated
19 August 2024

Who can take part

Age
Up to 18 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 23 criteriaShow less

Who can take part

  • Cohort 1: - Biologic Basis of JIA
  • ≤18 years*
  • Active objective arthritis suspected to be JIA or diagnosed with JIA within 6 months of enrolment
  • Treatment naïve except for NSAIDs, allowed to have received NSAIDS within 6 months of diagnosis; Cohort 2 - Start Biologics
  • JIA diagnosis as per ILAR criteria (all subtypes)
  • ≤18 years*
  • Active arthritis
  • For sJIA, active disease not necessarily with arthritis
  • Time of start, restart or switch biologic therapy: e.g. failure, insufficient/partial response or intolerance; Cohort 3 - Stop Biologics
  • JIA diagnosis as per ILAR criteria (all subtypes)
  • ≤18 years*
  • Inactive disease
  • Discontinuing/tapering biologics for inactive disease; Cohort 4: Extreme Phenotypes
  • Unexplained systemic inflammation with arthritis/arthralgia as a part of manifestations
  • High suspicion of genetic contribution
  • Severely affected patients with difficult to control disease (ie failure of multiple biologics)

Who cannot take part

  • Joint injections as previous treatment less than 4 weeks prior to enrollment; Cohort 2:
  • Cohort 1 :
  • Arthritis explained by another diagnosis
  • Arthritis explained by any other cause
  • Start on biologics as an indication for uveitis only; Cohort 3:
  • Tapering scheme > 12 months to complete biologics stop; Cohort 4:
  • Arthritis explained by another diagnosis

This trial has no sites in United States.

It has sites in 2 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

Childhood arthritis is a chronic disabling disease. New medications called biologic therapies are now available to treat arthritis that target key biologic molecules that cause inflammation. Biologic therapies, while very effective in treating arthritis in children, may have serious side effects including infections and potentially cancers, and are very expensive and doctors don't know, which one to choose for which child. The investigators will develop tests that enable them to learn about the biology of each child's arthritis and be able to predict when and which biologic therapy to start and when to stop.

The 4 groups in the trial

  • Cohort 1 - Biologic Basis of JIA

    The objectives for this group are to help researchers look at childhood arthritis and determine which management approach is best for each individual child. To be eligible for this group: Participant must be ≤ 18 years of age at time of study enrollment. Participant is suspected to have JIA. Participant has not received any treatment other than non-steroidal anti-inflammatory drugs, such as acetaminophen.

  • Cohort 2 - Start Biologics

    The objectives for this group are to help researchers develop a tool to predict response to therapy. To be eligible for this group: Participant ≤ 18 years of age at time of study enrollment. Participant has been diagnosed with JIA and arthritis is active. Participant will be starting, re-starting or switching to a new biologic therapy.

  • Cohort 3 - Stop Biologics

    The objectives for this group are to help researchers develop a tool to predict who will remain in remission after discontinuing therapy. To be eligible for this group: Participant ≤ 18 years of age at time of study enrollment. Participant has been diagnosed with JIA and arthritis is inactive. Participant will be stopping or tapering biologic therapy.

  • Cohort 4: Extreme Phenotypes

    The objective for this group is new gene discovery and drug target identification. To be eligible for this group: There is high suspicion of genetic contribution. Participants are severely affected with difficult to control arthritis or systemic disease. There is unexplained systemic inflammation with arthritis/arthralgia as a part of manifestations

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
19 August 2024